Notice of Interim Results

RNS Number : 2575X
Oxford Biomedica PLC
27 August 2020
 

 

 

Notice of Interim Results

 

 

 

Oxford, UK - 27 August, 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2020 on Thursday 17 September 2020.

 

A virtual briefing and Q&A session for analysts will be held at 13.00 BST / 08.00 EST on the day of results, and the presentation and webcast details will be made available on the Group's website at www.oxb.com . A replay webcast will be made available shortly afterwards.

 

 

-Ends-

Enquiries:

 

 

Oxford Biomedica plc

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR

 

 

 

 

T: +44 (0)1865 783 000

T: +44 (0)1865 783 000

T: +44 (0)1865 954 161 / E: ir@oxb.com

 

 

Consilium Strategic Communications

 

Mary-Jane Elliott / Matthew Neal

 

 

 

T: +44 (0)20 3709 5700 /

 

 

 

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORQQLFLBVLEBBQ
UK 100

Latest directors dealings